Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321621 | 1.00 | DYRK1A (0.47) | DYRK1ADYRK1BTAS1R3TAS1R1HDAC1 | |
| Trifluoroacetic Acid SCHEMBL10321622 | 0.83 | TAS1R3 (0.45) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| Trifluoroacetic Acid SCHEMBL10319963 | 0.83 | TAS1R3 (0.45) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| Trifluoroacetic Acid SCHEMBL10319961 | 0.81 | DYRK1A (0.44) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| Trifluoroacetic Acid SCHEMBL10321620 | 0.81 | DYRK1A (0.44) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| SCHEMBL10317811 | 0.80 | TAS1R3 (0.50) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| SCHEMBL10318762 | 0.80 | TAS1R3 (0.50) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| SCHEMBL10320709 | 0.80 | TAS1R3 (0.50) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| SCHEMBL10318759 | 0.78 | TAS1R3 (0.48) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 | |
| SCHEMBL10317809 | 0.78 | TAS1R3 (0.48) | DYRK1ADYRK1BTAS1R3TAS1R1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | GOT1, PPARG, PPARA | DYRK1A 2480/4885DYRK1B 3023/4885TAS1R3 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.